Nkarta to Participate in Upcoming Investor Conference
Nkarta, a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, at 12:30 p.m. ET, featuring a fireside chat.
Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website (www.nkartatx.com). For those unable to attend live, a replay of the webcast will be archived on the website for approximately 90 days. This conference participation provides an opportunity for Nkarta to showcase its progress and engage with the investment community.
Nkarta, un'azienda biopharmaceutica specializzata in terapie con cellule natural killer (NK) ingegnerizzate, ha annunciato la sua partecipazione al prossimo 26° Annual Global Investment Conference di H.C. Wainwright. L'evento è previsto per il 10 settembre 2024, alle 12:30 p.m. ET, e includerà una conversazione informale.
Investitori e parti interessate possono accedere a un webcast dal vivo dell'evento attraverso la sezione Investitori del sito web di Nkarta (www.nkartatx.com). Per coloro che non possono partecipare dal vivo, una registrazione del webcast sarà archiviata sul sito per circa 90 giorni. La partecipazione a questa conferenza offre a Nkarta l'opportunità di mostrare i suoi progressi e interagire con la comunità degli investitori.
Nkarta, una empresa biofarmacéutica especializada en terapias con células asesinas naturales (NK) diseñadas, ha anunciado su participación en la próxima 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright. El evento está programado para el 10 de septiembre de 2024, a las 12:30 p.m. ET, con una charla informal.
Los inversores y partes interesadas pueden acceder a un webcast en vivo del evento a través de la sección de Inversores del sito web de Nkarta (www.nkartatx.com). Para aquellos que no puedan asistir en vivo, una repetición del webcast será archivada en el sitio durante aproximadamente 90 días. La participación en esta conferencia brinda a Nkarta la oportunidad de mostrar su progreso y relacionarse con la comunidad inversora.
Nkarta는 엔지니어링된 자연 킬러(NK) 세포 치료법을 전문으로 하는 바이오제약 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 10일 오후 12:30 ET에 예정되어 있으며, 불꽃 회의 형태로 진행됩니다.
투자자와 관심 있는 분들은 Nkarta 웹사이트 (www.nkartatx.com)의 투자자 섹션을 통해 이벤트의 실시간 웹캐스트에 접근할 수 있습니다. 실시간 참석이 불가능한 경우, 웹캐스트의 재방송은 약 90일 동안 웹사이트에 보관됩니다. 이 회의 참여는 Nkarta가 자신의 발전을 보여주고 투자 커뮤니티와 소통할 수 있는 기회를 제공합니다.
Nkarta, une entreprise biopharmaceutique spécialisée dans les thérapies par cellules tueuses naturelles (NK) Ingénierie, a annoncé sa participation à la prochaine 26e Conférence Annuelle Globale d'Investissement de H.C. Wainwright. L'événement est prévu le 10 septembre 2024 à 12h30 ET, comprenant un échange informel.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de l'événement via la section Investisseurs du site web de Nkarta (www.nkartatx.com). Pour ceux qui ne peuvent pas assister en direct, une rediffusion du webinaire sera archivée sur le site pendant environ 90 jours. La participation à cette conférence offre à Nkarta l'occasion de présenter ses progrès et d'interagir avec la communauté d'investissement.
Nkarta, ein biopharmazeutisches Unternehmen, das sich auf engineered natural killer (NK) Zelltherapien spezialisiert hat, hat seine Teilnahme an der bevorstehenden 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet am 10. September 2024 um 12:30 Uhr ET statt und umfasst ein informelles Gespräch.
Investoren und Interessierte können über den Investorenbereich der Website von Nkarta (www.nkartatx.com) auf einen live-Webcast der Veranstaltung zugreifen. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung des Webcasts ungefähr 90 Tage lang auf der Website archiviert. Die Teilnahme an dieser Konferenz bietet Nkarta die Gelegenheit, seine Fortschritte zu präsentieren und mit der Investitionsgemeinschaft in Kontakt zu treten.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
H.C. Wainwright 26th Annual Global Investment Conference
September 10, 2024
12:30 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
When is Nkarta (NKTX) participating in the H.C. Wainwright Global Investment Conference?
How can investors access Nkarta's (NKTX) presentation at the investor conference?
For how long will the replay of Nkarta's (NKTX) investor conference presentation be available?
What type of therapies does Nkarta (NKTX) develop?
